MRC Funding Update UKRI: Grants Reopened

MRC funding update, in brief: the Medical Research Council paused several applicant-led grant schemes from February 2026 while UK Research and Innovation restructured to an “always open” application model; research grants, new investigator grants and partnership grants reopened on 7 April 2026, experimental medicine opportunities reopened on 30 April 2026, and MRC Proof of Concept and Impact Acceleration Awards are scheduled to reopen in July 2026. For grant holders, the practical implications are a new rolling submission window, a consolidated review structure, and firm caps on how many applications one person can lead at once.

The MRC funding update ukri has published since February 2026 marks the most significant procedural change to Medical Research Council grant administration in over a decade. Medical Research Council (MRC) is one of UK Research and Innovation’s seven disciplinary councils, responsible for funding biomedical and health research across the UK’s higher education and institute sector. This briefing sets out exactly what changed, what remains open, and what research administrators and principal investigators need to do differently when planning 2026 applications.

• What actually changed in the MRC funding update
• Reopening timeline: what’s open now and what’s still paused
• The new College of Experts review structure
• Application caps and resubmission rules grant holders must know
• Budget signals: what the wider UKRI settlement means
• Frequently asked questions
• Implications for institutions and grant holders

What actually changed in the MRC funding update

On 1 February 2026, UKRI Chief Executive Ian Chapman issued an open letter to the research and innovation community announcing a new investment approach for the 2026–2030 spending review period. The letter described a shift toward a “more strategic, UKRI-wide model” for funding decisions, and confirmed that MRC would use the transition to refresh its approach to applicant-led funding.

The headline structural change is a move to an “always open” responsive-mode system, replacing fixed application deadlines. UKRI states that published deadlines “cause significant variation in the volume of applications we receive and in reviewer availability,” and that removing them smooths these peaks and troughs. This is an operating-model change, not a funding cut — MRC says curiosity-driven research remains a committed priority, underpinned by a UKRI-wide 50% budget commitment to that category of research.

To implement the “always open” system, MRC had to pause several applicant-led funding opportunities from February 2026 while the assessment infrastructure was rebuilt. Awards that had already been offered, accepted or started were explicitly unaffected throughout the transition.

Reopening timeline: what’s open now and what’s still paused

As of the most recent UKRI update (15 June 2026), most MRC applicant-led schemes have reopened. Grant holders should treat the table below as the operative reference, not the earlier February pause notice, which is now superseded.

UKRI expects the wider transition to be complete by the start of the 2027–2028 financial year (6 April 2027 to 5 April 2028). Institutions running internal peer-review or costing pipelines timed to the old deadline calendar should recalibrate now: under “always open” mode, there is no annual cycle to plan around.

The new College of Experts review structure

MRC’s four disciplinary research boards — covering infections and immunity, molecular and cellular medicine, neurosciences and mental health, and population and systems medicine — have been consolidated into a single College of Experts. Funding panels are now drawn flexibly from this combined pool rather than fixed to a single board.

This restructuring supports cross-disciplinary applications that previously sat awkwardly between boards, and enables faster decisions by decoupling panel composition from a rigid quarterly schedule. Applications closed before the transition — including the legacy boards’ November 2025 round and Developmental Pathway Funding Scheme stage two — are still assessed under the old structure, with decisions expected in April 2026; MRC has confirmed a reduced number of awards from that backlog, reflecting the changeover rather than any change in typical grant size going forward.

Application caps and resubmission rules grant holders must know

Two new eligibility mechanics apply under the “always open” model and directly affect how principal investigators should sequence their applications:

• Application cap: a maximum of two applications as project lead may be submitted across applicant-led responsive-mode funding calls within any rolling 12-month period.
• Resubmission bar: an application previously unsuccessful with MRC — or with any other funder — will not be considered again for 12 months, unless MRC has explicitly invited a resubmission.
• Cost basis unchanged: MRC continues to fund 80% of the full economic cost (FEC), with grant durations ranging from 18 months to five years and no fixed cap on requested amount, provided the sum is proportionate to project scope.

For research offices, “always open” does not mean unlimited throughput per investigator — it shifts the constraint from a calendar deadline to a rolling personal quota. Grant-writing capacity planning built around a fixed autumn or spring deadline now needs continuous tracking of each investigator’s rolling 12-month application count.

Budget signals: what the wider UKRI settlement means

UKRI has stated that its overall research and innovation budget is rising across the 2026–2030 spending review period, and that the budget for biomedical and health research specifically is “in an excellent position.” Independent analysis from the Campaign for Science and Engineering notes that the overall UKRI budget is set to rise toward £10 billion a year by 2030, though how that funding is distributed across councils and themes is shifting considerably as part of the same restructuring.

A parallel strand channels additional funding through the UKRI Life Sciences Priority Programme — a cross-council theme through which MRC accesses coordinated funding beyond its standalone curiosity-driven allocation. UKRI frames this as additive: fellowships, studentships and Centres of Research Excellence funding was unaffected throughout, and the pause applied only to specific applicant-led schemes during infrastructure changes.

BBSRC underwent the same “always open” transition in parallel; its new investigator award and standard research grant have also reopened. Grant holders working across MRC and BBSRC funding lines should expect the same rolling-quota and resubmission mechanics on both councils, since the operating model is shared across the UKRI-wide transition rather than council-specific.

Frequently asked questions

Why did MRC pause its funding opportunities in 2026?

MRC paused several applicant-led schemes from February 2026 to implement UKRI’s move to an “always open” application system. UKRI stated that fixed deadlines caused uneven application volumes and reviewer availability problems, and that removing them required behind-the-scenes changes to assessment infrastructure before reopening.

Which MRC grants have reopened?

Applicant-led research grants, new investigator research grants and partnership grants reopened on 7 April 2026, and experimental medicine opportunities reopened on 30 April 2026. MRC Proof of Concept and MRC Impact Acceleration Awards are scheduled to reopen in July 2026.

Were MRC fellowships and studentships affected?

No. MRC has confirmed that funding for fellowships, studentships, and MRC Centres of Research Excellence was not affected by the 2026 pause and remained continuously open for applications throughout the transition period.

How many MRC applications can one person lead at once?

Under the new rules, a principal investigator may lead a maximum of two applications across applicant-led responsive-mode funding calls within any rolling 12-month period, and unsuccessful applications face a 12-month resubmission bar unless MRC has invited one.

Implications for institutions and grant holders

Research offices should update three things now. First, replace deadline-driven internal sign-off calendars with continuous submission tracking, since “always open” removes the predictable peaks institutions have historically planned costing and QA cycles around. Second, build a per-investigator rolling application count into grants-management systems to enforce the two-applications-per-12-months cap before a proposal reaches MRC and is rejected on eligibility grounds. Third, brief investigators explicitly on the 12-month resubmission bar — a previously unsuccessful proposal, even a strong one, is not eligible for quick resubmission without an explicit MRC invitation, which changes revision strategy considerably.

MRC has said it will continue to share updates and reopen remaining funding opportunities as they become ready, with full transition to the new model expected by April 2027. Institutions with active or upcoming submissions should monitor the MRC application timeline directly rather than relying on the February 2026 pause notice, which the June 2026 update has substantially superseded.